EGFR and non-small cell lung carcinoma: Regarding clinical investigation, SYMPHONY (NCT04862780) is a phase I/II clinical trial that is currently recruiting patients with EGFR-mutant NSCLC after failure of third-generation EGFR-TKIs, aiming to assess the safety, tolerability, and anticancer activity of BLU-945 with or without osimertinib.